MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cellectis Inc.

< Previous 1 2 3 Next >
News headline image
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers AZN CLLS
News headline image
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Tickers AZN CLLS
News headline image
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
News headline image
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story